¼¼°èÀÇ °£¾Ï ½ÃÀå º¸°í¼­(2025³â)
Liver Cancer Global Market Report 2025
»óǰÄÚµå : 1730931
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,253,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,039,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,824,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°£¾Ï ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 14.3%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 57¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ³ëÀÎ Àα¸ÀÇ È®´ë, ÇコÄɾî ÁöÃâÀÇ Áõ°¡, Àúħ½À Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Àü¹® Ŭ¸®´Ð Áõ°¡, ÀÇ·á Åõ¾î¸®Áò ¼ºÀå¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ ±â°£ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Áø´Ü ±â¼úÀÇ ¹ßÀü, Ç¥Àû ¿ä¹ýÀÇ °³¹ß, º´¿ë ¿ä¹ýÀÇ µµÀÔ, ¿Ü°ú ¼ö¼úÀÇ ±â¼ú Çõ½Å, ¹æ»ç¼± Ä¡·á ±â¼úÀÇ Áøº¸ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¾ËÄÚ¿Ã ¼Òºñ·® Áõ°¡°¡ °£¾Ï ½ÃÀåÀÇ È®´ë¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ËÄÚ¿Ã ¼Òºñ·®Àº ±× ¾ç°ú ºóµµ¿¡ ÀÇÇØ ÃøÁ¤µÇ´Â °ÍÀÌ ÀϹÝÀûÀÌÁö¸¸, ¹Ìµð¾î¿¡¼­ ¼±ÀüµÇ¾î ´Ù¾çÇÑ »óȲ¿¡¼­ ÀÔ¼öÇϱ⠽¬¿öÁüÀ¸·Î½á »ç¶÷µéÀÌ ÀÏ»óÀÇ ½ºÆ®·¹½º¸¦ ÇØ¼ÒÇÏ°í »çȸÀû ±³·ù¸¦ ÃËÁøÇÏ¸ç ¸±·º½º È¿°ú¸¦ ³ôÀÌ´Â µ¥ µµ¿òÀÌ µÇ°í Àֱ⠶§¹®¿¡ Áõ°¡ ÀϷθ¦ °È°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¾ËÄÚ¿ÃÀÇ °ú´Ù¼·Ãë´Â °£°æº¯À̳ª ¿°Áõ, DNAÀÇ ¼Õ»óÀ» À¯¹ßÇÏ°í ¼¼Æ÷ÀÇ ÀÌ»óÁõ½ÄÀ» ÃËÁøÇÔÀ¸·Î½á °£¾ÏÀÇ À§ÇèÀ» ³ôÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 3¿ù ¾ÆÀÏ·£µå¿¡ ±â¹ÝÀ» µÐ µ¥ÀÌÅÍ ¼öÁý ±â°ü National Drugs Library´Â 15¼¼ ÀÌ»ó °³ÀÎÀÇ Æò±Õ ¾ËÄÚ¿Ã ¼Òºñ·®ÀÌ 2022³â¿¡´Â 1ÀÎ´ç ¼ø ¾ËÄÚ¿Ã 10.2¸®ÅÍ·Î Áõ°¡Çß°í, 2021³âºÎÅÍ 7.6% Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ ¾ËÄÚ¿Ã ¼Òºñ·®ÀÇ Áõ°¡°¡ °£¾Ï ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

°£¾Ï ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Ä¡·á Á¤¹Ðµµ Çâ»ó, ȯÀÚ °á°ú °³¼±, ºÎÀÛ¿ë ¿ÏÈ­¸¦ ¸ñÇ¥·Î ÇÏ¿©, ¼±Áø Ä¡·á ±â±â, ƯÈ÷ °æ Ä«Å×ÅÍÀû µ¿¸Æ È­ÇÐ »öÀü ¿ä¹ý(TACE)ÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. TACE´Â Ä¡·á È¿°ú¸¦ ³ôÀ̱â À§ÇØ Ç÷¾× °ø±ÞÀ» Â÷´ÜÇϸ鼭 È­Çпä¹ýÀ» °£ Á¾¾ç¿¡ Á÷Á¢ Åõ¿©ÇÏ´Â Àúħ½À ¼ö¼úÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ÀϺ»ÀÇ ÀÇ·á ±â¼ú ±â¾÷ÀÎ Å׸£¸ð ÁÖ½Äȸ»ç´Â 2023³â 11¿ù °£¾Ï °ü¸®¸¦ Áö¿øÇÏ´Â 2°³ÀÇ Çõ½ÅÀûÀÎ Ä¡·á ±â±âÀÎ Oclusafe¿Í LifePearlÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ±â±âµéÀº Àεµ¿¡¼­ °¡Àå ÈçÇÑ ¿ø¹ß¼º °£¾ÏÀÎ °£¼¼Æ÷¾Ï(HCC)ÀÇ Ä¡·á¸¦ °³¼±Çϱâ À§ÇØ ¼³°èµÆÀ¸¸ç ¸Å³â 2¸¸ ¸í ÀÌ»óÀÇ ½Å±Ô ȯÀÚ°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. Occlusafe´Â Balloon-TACE(B-TACE)·Î ¾Ë·ÁÁø ÃÖ÷´Ü Ä¡·á¹ýÀÇ ÀϺηÎ, ¼Õ±â¼ú Áß Ç³¼±À» »ç¿ëÇÏ¿© Ç÷·ù¸¦ Â÷´ÜÇÔÀ¸·Î½á TACEÀÇ Á¤È®µµ ¹× È¿°ú¸¦ ³ôÀÔ´Ï´Ù. ¶óÀÌÇÁ ÆÞÀº Æú¸®¿¡Æ¿·»±Û¸®ÄÝ(PEG) »öÀü ¹Ì¼Ò±¸·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç È­Çпä¹ýÁ¦¸¦ ÃæÀüÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Liver cancer is a type of malignant disease that begins in the liver cells, primarily hepatocytes, and has the potential to spread to other organs. It is linked to risk factors such as chronic infections with hepatitis B and C, cirrhosis, excessive alcohol use, and non-alcoholic fatty liver disease (NAFLD). The disease is often diagnosed in its advanced stages, making early detection and treatment essential for improving survival rates.

The main forms of liver cancer include hepatoblastoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and fibrolamellar carcinoma. Hepatoblastoma is a rare form of liver cancer that typically affects young children and arises from immature liver cells. Liver cancer progresses through various stages, including the early, intermediate, and advanced stages. Treatment options include targeted therapy, radiation therapy, surgery, chemotherapy, and immunotherapy. The primary end users of these treatments are hospitals, specialty clinics, ambulatory surgical centers, and cancer research institutes.

The liver cancer market research report is one of a series of new reports from The Business Research Company that provides liver cancer market statistics, including the liver cancer industry global market size, regional shares, competitors with the liver cancer market share, detailed liver cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the liver cancer industry. This liver cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The liver cancer market size has grown rapidly in recent years. It will grow from $2.94 billion in 2024 to $3.37 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth during the historic period can be attributed to the increasing global incidence of liver cancer, the rising prevalence of hepatitis B and C infections, higher rates of non-alcoholic fatty liver disease, government initiatives encouraging early diagnosis, and growing awareness about liver health.

The liver cancer market size is expected to see rapid growth in the next few years. It will grow to $5.75 billion in 2029 at a compound annual growth rate (CAGR) of 14.3%. The growth during the forecast period can be attributed to the expanding geriatric population, higher healthcare spending, increasing demand for minimally invasive treatments, a rise in specialty clinics, and the growth of medical tourism. Key trends during this period include advancements in diagnostic technologies, the development of targeted therapies, the introduction of combination therapies, technological innovations in surgical procedures, and progress in radiotherapy techniques.

The growing consumption of alcohol is expected to drive the expansion of the liver cancer market. Alcohol consumption, typically measured by its quantity and frequency, has been rising as it helps people relieve daily stress, fosters social interaction, and enhances relaxation, with its promotion in media and increased accessibility in various settings. However, excessive alcohol intake can lead to liver cirrhosis, inflammation, and DNA damage, which increases the risk of liver cancer by encouraging abnormal cell growth. For example, in March 2023, the National Drugs Library, an Ireland-based data collection organization, reported that the average alcohol consumption for individuals aged 15 and older increased to 10.2 liters of pure alcohol per capita in 2022, reflecting a 7.6% rise from 2021. This increase in alcohol consumption is contributing to the growth of the liver cancer market.

Leading companies in the liver cancer market are focusing on developing advanced therapy devices, specifically transcatheter arterial chemoembolization (TACE), to improve treatment precision, patient outcomes, and reduce side effects. TACE is a minimally invasive procedure that delivers chemotherapy directly to a liver tumor while blocking its blood supply to increase the treatment's effectiveness. For example, in November 2023, Terumo Corporation, a Japan-based medical technology company, launched two innovative therapy devices, Occlusafe and LifePearl, to assist in the management of liver cancer. These devices are designed to improve the treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer in India, which sees over 20,000 new cases each year. Occlusafe is part of a cutting-edge therapy known as Balloon-TACE (B-TACE), which increases the precision and effectiveness of TACE by using a balloon to block blood flow during the procedure. LifePearl consists of polyethylene glycol (PEG) embolization microspheres, which can be loaded with chemotherapeutic agents.

In August 2023, TriSalus Life Sciences, a U.S.-based medical technology company focused on oncology, merged with MedTech Acquisition Corporation. This merger is intended to strengthen TriSalus Life Sciences' financial position and support the development of innovative treatments for liver and pancreatic tumors. MedTech Acquisition Corporation is a special purpose acquisition company (SPAC) that targets mergers with existing medical technology firms.

Major players in the liver cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Siemens Healthineers AG, Terumo Corporation, Eisai Co. Ltd., Qiagen N.V., Exelixis Inc., BeiGene Ltd., RayzeBio Inc., Innovent Biologics Inc., Celsion Corporation.

North America was the largest region in the liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the liver cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liver cancer market consists of revenues earned by entities providing services such as early screening, palliative care, liver transplantation, personalized medicine, and radiofrequency ablation. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer market also includes sales of diagnostic imaging equipment, biomarker tests, embolization devices, and supportive care medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for liver cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Liver Cancer Market Characteristics

3. Liver Cancer Market Trends And Strategies

4. Liver Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Liver Cancer Growth Analysis And Strategic Analysis Framework

6. Liver Cancer Market Segmentation

7. Liver Cancer Market Regional And Country Analysis

8. Asia-Pacific Liver Cancer Market

9. China Liver Cancer Market

10. India Liver Cancer Market

11. Japan Liver Cancer Market

12. Australia Liver Cancer Market

13. Indonesia Liver Cancer Market

14. South Korea Liver Cancer Market

15. Western Europe Liver Cancer Market

16. UK Liver Cancer Market

17. Germany Liver Cancer Market

18. France Liver Cancer Market

19. Italy Liver Cancer Market

20. Spain Liver Cancer Market

21. Eastern Europe Liver Cancer Market

22. Russia Liver Cancer Market

23. North America Liver Cancer Market

24. USA Liver Cancer Market

25. Canada Liver Cancer Market

26. South America Liver Cancer Market

27. Brazil Liver Cancer Market

28. Middle East Liver Cancer Market

29. Africa Liver Cancer Market

30. Liver Cancer Market Competitive Landscape And Company Profiles

31. Liver Cancer Market Other Major And Innovative Companies

32. Global Liver Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liver Cancer Market

34. Recent Developments In The Liver Cancer Market

35. Liver Cancer Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â